menu
    • menu
    [{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNF1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Therapeutics \/ Danuo Science Group"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"EN-2642","moa":"EGFR-Fc","graph1":"Oncology","graph2":"Discovery","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Enosi Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Enosi Therapeutics

    Menu

    Enosi Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enosi Therapeutics

                            U.S.A arrow
                            The Aesthetic Show
                            Not Confirmed

                            Enosi Therapeutics

                            U.S.A arrow
                            The Aesthetic Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN-2642

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enosi Therapeutics to Present at the ENA 2022 Symposium on Molecular Targets and Cancer Therapeutics in Barcel...

                            Details : EN-2642 is an affinity EGFR-Fc: HER3:Fc ligand trap and binds 9 of 11 growth factors which activate HER family.Growth factors participate in progression of many diseases, including solid cancers and rheumatoid arthritis.

                            Product Name : EN-2642

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : EN-2642

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enosi Therapeutics

                            U.S.A arrow
                            The Aesthetic Show
                            Not Confirmed

                            Enosi Therapeutics

                            U.S.A arrow
                            The Aesthetic Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN1001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Danuo Science Group

                            Deal Size : $105.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs

                            Details : Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN1001) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases.

                            Product Name : EN1001

                            Product Type : Antibody

                            Upfront Cash : $5.0 million

                            May 07, 2022

                            Lead Product(s) : EN1001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Danuo Science Group

                            Deal Size : $105.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth